A variant of combined treatment for chronic central serous chorioretinopathy complicated by type 1 choroidal neovascularization

Purpose: to evaluate the effectiveness of combined treatment of chronic central serous chorioretinopathy (CSCRP) complicated by type 1 choroidal neovascularization (CNV) by subthreshold micropulse laser exposure (SMILE) and intravitreal injection of angiogenesis inhibitors ( IIAI). Material and methods. 37 patients (20 men and 17 women) with monolateral chronic recurrent CSCRP complicated by type 1 CNV, aged 35 to 57 (ave. 43.6 ± 6.7 yrs.) at the moment of first referral, were divided into two groups. The retrospective group included 15 patients (15 eyes) whose first phase of treatment consisted in IIAI (up to 5 injections with an interval of one month). Those who showed no treatment effect were given a SMILE procedure one day before the 6th injection. If neurosensory retinal detachment persisted, the combined treatment (SMILE + IIAI) was repeated monthly until the neurosensory retina could be fully attached, whereupon the patients were transferred to monotherapy with anti-VEGF injections, gradually increasing the interval between the injections. The main group included 22 patients (22 eyes), whose treatment began with a single IIAI. If no neurosensory retinal detachment resorption occurred, the patients received a SMILE procedure one day before the second IIAI injection. The combined treatment was repeated monthly until neurosensory retinal detachment completely resorbed, then the treatment continued with IIAI alone with a gradual increase of intervals between the injections. Results. The number of IIAI in the main group (5 to 8, ave. 6.1 ± 0.8) was significantly lower than in the retrospective group (8 to 10, ave. 8.8 ± 0.77). Best corrected visual acuity increased in both groups, but the main group showed a better central photosensitivity, which is associated with the faster reattachment of neurosensory retina. By the end of the follow-up period, the area of type 1 CNV, and the thickness of the choroid were significantly lower in the main group as compared to the retrospective group. The combined treatment did not cause a single case of complication. Conclusion. The proposed combination of laser exposure followed by IIAI is a safe method for treating complicated forms of CSCRP, which quickens the resorption of subretinal fluid and reduces the number of treatment procedures.

1. Liew G., Quin G., Gillies M., Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin. Exp. Ophthalmol. 2013; 41 (2): 201–14. doi: 10.1111/j.1442-9071.2012.02848.x

2. Kachalina G.F., Pedanova E.K., Solomin V.A., Klepinina O.B. Morphofunctional results of treatment of central serous chorioretinopathy in a subthreshold micro-pulse mode of laser exposure with a wavelength of 577 nm (preliminary report). Bulletin of the Orenburg State University. 2013; 153 (4): 127–30 (in Russian).

3. Wang M., Munch I.C., Hasler P.W., Prünte C., Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008; 86 (2): 126–45. doi: 10.1111/j.1600- 0420.2007.00889.x

4. Lee G.I., Kim A.Y., Kang S.W., et al. Factors and outcomes of choroidal neovascularization secondary to central serous chorioretinopathy. Sci Rep. 2019; 9 (1): 3927. doi: 10.1038/s41598-019-40406-y

5. Gupta B., Elagouz M., McHugh D., Chong V., Sivaprasad S. Micropulse diode laser photocoagulation for central serous chorio-retinopathy. Clin. Exper. Ophthalmol 2009; 37 (8): 801–5. doi: 10.1111/j.1442-9071.2009.02157.x

6. Shchegoleva I.V., Budzinskaya M.V. Etiology and pathogenesis of central serous chorioretinopathy. Bulletin of ophthalmology. 2010; 126 (3): 55–8 (in Russian).

7. Wang M., Sander B., Larsen M. Retinal atrophy in central serous chorioretinopathy. Am. J. Ophthalmol. 2002; 133 (6): 787–93 doi: 10.1016/ s0002-9394(02)01438-1

8. Dansingani K.K., Balaratnasingam C., Klufas M.A., Sarraf D., Freund K.B. Optical coherence tomography angiography of shallow irregular pigment epithelial detachments in pachychoroid spectrum disease. Am. J. Ophthalmol. 2015; 160 (6): 1243–54 e2. doi: 10.1016/j.ajo.2015.08.028

9. Bousquet E., Bonnin S., Mrejen S., et al. Optical coherence tomography angiography of flat irregular pigment epithelium detachment in chronic central serous chorioretinopathy. Retina. 2018; 38 (3): 629–38. doi: 10.1097/ IAE.0000000000001580

10. Miyake M., Tsujikawa A., Yamashiro K., et al. Choroidal neovascularization in eyes with choroidal vascular hyperpermeability. Invest. Ophthalmol. Vis. Sci. 2014; 55 (5): 3223–30. doi: 10.1167/iovs.14-14059

11. Shiragami C., Takasago Y., Osaka R., et al. Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization. Am. J. Ophthalmol. 2018; 193: 80–6. doi: 10.1016/j.ajo.2018.06.009

12. Quaranta-El M.M., El M.A., Eandi C.M. Chronic central serous chorioretinopathy imaged by optical coherence tomographic angiography. Am. J. Ophthalmol. 2015; 160 (3): 581–7 e1. doi: 10.1016/j.ajo.2015.06.016

13. Pang C.E., Freund K.B. Pachychoroid neovasculopathy. Retina. 2015; 35 (1): 1–9. doi: 10.1097/IAE.0000000000000331

14. Schworm B., Luft N., Keidel L.F., et al. Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. Graefes Arch. Clin. Exp. Ophthalmol. 2020; 258 (5): 1013–21. doi: 10.1007/s00417-020- 04623-w

15. De Carlo T.E., Bonini Filho M.A., Chin A.T., et al. Spectral- domain optical coherence tomography angiography of choroidal neovascularization. Ophthalmology. 2015; 122 (6): 1228–38. doi: 10.1016/j.ophtha.2015.01.029

16. Muakkassa N.W., Chin A.T., de Carlo T., et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina. 2015; 35 (11): 2252–9. doi: 10.1097/IAE.0000000000000836

17. Broadhead G., Chang A. Intravitreal aflibercept for choroidal neovascularisation complicating chronic central serous chorioretinopathy. Graefes Arch. Clin. Exp. Ophthalmol. 2015; 253 (6): 979–81. doi 10.1007/s00417-014-2891-0

18. Pitcher J., Witkin A., DeCroos F., Ho A. A prospective pilot study of intravitreal aflibercept for the treatment of chronic central serous chorioretinopathy: the CONTAIN study. Br. J. Ophthalmol. 2015; 99 (6): 848–52. doi: 10.1136/ bjophthalmol-2014-306018

19. Ng W.W., Wu Z.H., Lai T.Y. Half-dose verteporfin photodynamic therapy for bullous variant of central serous chorioretinopathy: a case report. J. Med. Case Rep. 2011; 5: 208. doi: 10.1186/1752-1947-5-208

20. Pryds A., Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol. 2012; 90 (8): 738–43. doi: 10.1111/j.1755-3768.2011.02157.

21. Shin J.Y., Woo S.J., Yu H.G., Park K.H. Comparison of efficacy and safety between half-fluence and full-fluence photodynamic therapy for chronic central serous chorioretinopathy. Retina. 2011; 31 (1): 119–26. doi: 10.1097/ IAE.0b013e3181e378f2

22. Uetani R., Ito Y., Oiwa K., Ishikawa K., Terasaki H. Half-dose vs one-thirddose photodynamic therapy for chronic central serous chorioretinopathy. Eye (Lond) 2012; 26 (5): 640–9. doi: 10.1038/eye.2012.66

23. Volodin P.L., Doga A.V., Ivanova E.V., et al. A personalized approach to the treatment of chronic central serous chorio-retinopathy based on the navigation technology of micropulse laser action. Ophthalmology. 2018; 15 (4): 394–404 (in Russian). doi: 10.18008/1816-5095-2018-4-394-404

24. Malinovskaya M.A., Dikovskaya M.A. The first experience of using subthreshold micro-pulsed laser exposure of 577 nm for choroidal neovascularization. Modern technologies in ophthalmology. 2018; 1: 245–9 (in Russian).

25. Prasuhn M., Miura Y., Tura A., et al. Influence of retinal microsecond pulse laser treatment in central serous chorioretinopathy: A short-term optical coherence tomography angiography study. J. Clin. Med. 2021; 10 (11): 2418. doi: 10.3390/ jcm10112418

26. Fung A.T., Yannuzzi L.A., Freund K.B. Type 1 (sub-retinal pigment epithelial) neovascularization in central serous chorioretinopathy masquerading as neovascular age-related macular degeneration. Retina. 2012; 32 (9): 1829–37. doi: 10.1097/IAE.0b013e3182680a66

27. Spaide R.F. Optical coherence tomography angiography signs of vascular abnormalization with antiangiogenic therapy for choroidal neovascularization. Am. J. Ophthalmol. 2015; 160 (1): 6–16. doi: 10.1016/j.ajo.2015.04.012

28. Sacconi R., Tomasso L., Corbelli E., et al. Early response to the treatment of choroidal neovascularization complicating central serous chorioretinopathy: an OCT-angiography study. Eye (Lond). 2019; 33 (11): 1809–17. doi: 10.1038/ s41433-019-0511-2

29. Wu J.-S., Chen S.-N. Optical coherence tomography angiography for diagnosis of choroidal neovascularization in chronic central serous chorioretinopathy after photodynamic therapy. Sci. Rep. 2019; 9 (1): 9040. doi: 10.1038/s41598- 019-45080-8

30. Loo R.H., Scott I.U., Flynn Jr H.W., et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina. 2002; 22 (1): 19–24. doi: 10.1097/00006982- 200202000-00004

31. Spaide R.F., Campeas L., Haas A., et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996; 103 (12): 2070–9. doi: 10.1016/ S0161-6420(96)30386-2

32. Demirel S., Yanık Ö., Nalcı H., Batıoğlu F., Özmert E. The use of optical coherence tomography angiography in pachychoroid spectrum diseases: a concurrent comparison with dye angiography. Graefes Arch. Clin. Exp. Ophthalmol. 2017; 255 (12): 2317–24. doi: 10.1007/s00417-017-3793-8

33. Carnevali A., Capuano V., Sacconi R., et al. Optical coherence tomography angiography of treatment-naïve quiescent choroidal neovascularization in pachychoroid neovasculopathy. Ophthalmol. Retina. 2017; 1 (4): 328–32. doi: 10.1016/j.oret.2017.01.003

34. Popova N.V., Gojdin A.P. Application of micropulse laser exposure in central serous chorioretinopathy. Practical medicine. 2016; 6 (98): 137–40 (in Russian).

35. Popova N.V., Fabrikantov O.L., Gojdin A.P. Comparative analysis of the use of suprathreshold laser coagulation and micropulse laser exposure in central serous chorioretinopathy. Saratov Journal of Medical Scientific Research. 2019: 15 (2): 532–6 (in Russian).